Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02270606
Other study ID # MCC-14-10491
Secondary ID NCI-2014-02089P3
Status Completed
Phase Phase 1
First received
Last updated
Start date December 4, 2014
Est. completion date May 13, 2021

Study information

Verified date July 2021
Source Virginia Commonwealth University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving additional combination chemotherapy after surgery may kill any remaining tumor cells. Giving radiation therapy and fluorouracil followed by combination chemotherapy before and after surgery may be a better treatment for rectal cancer.


Description:

OUTLINE: This is a dose-escalation study of fluorouracil. CHEMORADIATION: Patients undergo intensity-modulated radiation therapy (IMRT) once daily (QD) over 5 days for a total of 5 fractions and concurrently receive fluorouracil intravenously (IV) continuously over 96 hours. PREOPERATIVE CHEMOTHERAPY: Within 2 weeks of completing chemoradiation, patients receive oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV as a push followed by IV continuously over 46 hours on day 1. Treatment repeats every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity. SURGERY: Within 4-8 weeks of completing preoperative chemotherapy, patients undergo total mesorectal excision. POSTOPERATIVE CHEMOTHERAPY: Within 4-8 weeks after surgery, patients receive oxaliplatin, leucovorin calcium, and fluorouracil as in preoperative chemotherapy. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 1 year or until removal from the study or death, whichever occurs first.


Recruitment information / eligibility

Status Completed
Enrollment 14
Est. completion date May 13, 2021
Est. primary completion date May 14, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Pathologically proven diagnosis of adenocarcinoma of the rectum (located below the peritoneal reflection or begins within 15 cm of the anal verge on flexible endoscopy) within 90 days of registration; diagnosis of rectal adenocarcinoma must be obtained by biopsy technique that does not completely excise the lesion (eg, fine needle aspiration, core needle biopsy) - Clinically determined to be clinically staged (American Joint Committee on Cancer (AJCC) 7th edition [ed.]) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup within 90 days prior to registration: - Colonoscopy - History/physical examination (including medication history screen for contraindications) - Contrast-enhanced imaging of the abdomen and pelvis either by computed tomography (CT), magnetic resonance imaging (MRI), or whole body positron emission tomography (PET)-CT (preferred) - Chest x-ray (or CT) of the chest to exclude distant metastases (except for those who have had whole body PET-CT per above bullet point) - Transrectal ultrasound (TRUS) or MRI for T staging - Eastern Cooperative Oncology Group (ECOG) performance status =< 1 - Absolute neutrophil count (ANC) >= 1,800 cells/mm^3 - Platelets >= 100,000 cells/mm^3 - Hemoglobin >= 8.0 g/dL (note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dL is acceptable) - Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN) - Alkaline phosphatase < 2.5 x ULN - Bilirubin =< 1.5 ULN - Calculated creatinine clearance (CrCl) > 50 mL/min using Cockcroft-Gault formula - Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation - Must provide study-specific informed consent prior to study entry - Must have a negative serum pregnancy test Exclusion Criteria: - Prior radiotherapy to the region of the body that would result in overlap of RT fields with the current protocol treatment - Severe, active comorbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 12 months - Transmural myocardial infarction within the last 6 months - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol - Evidence of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of treatment protocol or follow up - Known, existing uncontrolled coagulopathy; subjects on therapeutic anticoagulation may be enrolled provided that they have been clinically stable on anti-coagulation for at least 2 weeks - Major surgery within 28 days of study enrollment (other than diverting colostomy) - Crohn's disease or ulcerative colitis requiring hospitalization, surgery or immunosuppressive medications - Prior allergic reaction to 5-Fluorouracil or oxaliplatin - Any evidence of distant metastases (M1) - Extension of malignant disease into the anal canal - Pregnant as determined by a positive serum pregnancy test within 14 days prior to registration on study (for females of childbearing potential)

Study Design


Intervention

Radiation:
intensity-modulated radiation therapy
Undergo IMRT
Drug:
fluorouracil
Given IV
oxaliplatin
Given IV
leucovorin calcium
Given IV
Procedure:
therapeutic conventional surgery
Undergo total mesorectal excision

Locations

Country Name City State
United States Virginia Commonwealth University/Massey Cancer Center Richmond Virginia

Sponsors (2)

Lead Sponsor Collaborator
Virginia Commonwealth University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity for continuous infusional 5-Fluorouracil given concurrently with short course pelvic radiation To determine the maximum tolerated dose of continuous infusional 5-Fluorouracil, up to a target dose of 200 mg/m^2/day, given concurrently with short course radiation followed by neoadjuvant FOLFOX chemotherapy and planned surgical resection for locally advanced rectal cancer. Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4. Up to 21 days
Secondary Pathological response rate for subjects treated with concurrent 5-FU To determine the rates of pathologic response for subjects treated with 5-FU together with neoadjuvant, short course pelvic RT. Up to at least 5 years
Secondary Complete response rate with radiographic imaging prior to surgery To determine the rate of complete response prior to surgery. Up to 8 weeks after completion of pre-operative chemotherapy
Secondary Three-year rate of local-regional recurrence for all subjects enrolled on the study To determine the rates of local-regional recurrence for subjects treated with 5-FU together with neoadjuvant, short course pelvic RT. 3 years
Secondary Adverse events at any time To determine the incidence of all toxicity (gastrointestinal and non-gastrointestinal) associated with protocol treatment in the preoperative period, the postoperative period, and therefore assess the tolerability of the combination regimen. 30 days after surgery
Secondary Three-year rate of disease-free survival for all subjects enrolled on the study To determine the disease-free survival for subjects treated with 5-FU together with neoadjuvant, short course pelvic RT. 3 years
Secondary Postoperative morbidity rates Up to 30 days after surgery
Secondary Postoperative mortality rates Up to 30 days after surgery
See also
  Status Clinical Trial Phase
Completed NCT01987726 - Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors
Active, not recruiting NCT00826540 - Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT00025337 - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Phase 3
Recruiting NCT04642924 - SGM-101 in Locally Advanced and Recurrent Rectal Cancer Phase 2/Phase 3
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01217450 - Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors Phase 1
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01238965 - Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01285102 - Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Completed NCT00551421 - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT00407654 - VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Terminated NCT00052585 - Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer Phase 2
Completed NCT00023933 - Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer Phase 1
Not yet recruiting NCT05076305 - PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
Completed NCT01740648 - Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer Phase 1
Terminated NCT00397878 - AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer Phase 2
Completed NCT00100841 - Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Phase 2